Peripheral blood monocytes are plastic cells that migrate to tissues and differentiate into various cell types including macrophages, dendritic cells and osteoclasts. We have described the migration of cIAP1 (Inhibitor of Apoptosis Protein 1), a member of IAP family of proteins, from the nucleus to the Golgi apparatus in monocytes undergoing differentiation into macrophages. Here, we show that, once in the cytoplasm, cIAP1 is involved in the degradation of the adaptor protein TRAF2 by the proteosomal machinery. Inhibition of cIAP1 prevents the decrease in TRAF2 expression that characterizes macrophage formation. We demonstrate that TRAF2 is initially required for macrophage differentiation as its silencing prevents Iκ-Bα degradation, NF-κB p65 nuclear translocation and the differentiation process.
Introduction
Tumor necrosis factor (TNF) Receptor Associated Factors (TRAFs) form an evolutionarily conserved family of intracellular adaptors that bind directly or indirectly to members of the TNF receptor (TNFR) and the interleukin-1 (IL-1) / Toll-like receptor (TLR) families. 1, 2 They participate in the transduction of signals from these receptors to downstream events that regulate cell proliferation, differentiation and death.
The member of this family known as TRAF2 directly binds CD27, CD30, CD40, CD137, TNFR2 and Receptor Activator of Nuclear Factor-kappa B (RANK). TRAF2 can also bind TNFR1 indirectly, through interaction with TNF-receptor-associated death domain protein (TRADD). 3 Upon receptor engagement, TRAF2 is recruited in a receptor-associated multi-protein complex [4] [5] [6] where it contributes to stimulate specific downstream signalling pathways.
Depending on cell type, differentiation stage and stimulated receptors, these signalling pathways can involve c-jun N-terminal kinase (JNK), Nuclear Factor-kappa B (NF-κB), and p38 mitogen activated protein kinase (p38MAPK). 4, 5, [7] [8] [9] TRAF2 is also a key regulator of TNFR1-mediated apoptosis. [10] [11] [12] [13] TRAF2 activity is regulated by its interaction with protein partners such as TRAF1, 14-16 subcellular localisation, 7, 8, 15 ubiquitylation and degradation by the proteasome pathway. 8, 12, 13, [17] [18] [19] A yeast two-hybrid screen of proteins able to bind TRAF2 identified a direct interaction with cIAP1 (cellular Inhibitor of Apoptosis Protein 1, also named BIRC2, HIAP2), a member of the IAP family of proteins. 20, 21 Thanks to the presence of a C-terminal zinc finger domain (RING domain) that displays an E3-ubiquitin ligase activity, cIAP1 was demonstrated to promote TRAF2 ubiquitylation and to target the protein for proteasomemediated degradation. 12, 13, [22] [23] [24] For personal use only. on June 9, 2017 . by guest www.bloodjournal.org From
We have previously shown that cIAP1 was required for macrophage differentiation. 25 We have also shown that cIAP1 migrated from the nucleus to the cytoplasm to concentrate at the surface of the Golgi apparatus in monocytes undergoing differentiation into macrophages. 26 However, the role of cIAP1 and the functional significance of its differentiation-associated redistribution remained unknown. Here, we show that TRAF2 is initially required for the differentiation of monocytes into macrophages. Then, cIAP1 triggers its proteosomal degradation, which appears to be required for the normal outcome of the differentiation process. cIAP1 also maintains a low level of TRAF2 in differentiated macrophages, which favours the secretion of pro-inflammatory cytokines upon exposure to CD40 ligand (CD40L).
Materials and methods

Antibodies
The anti-human cIAP1 and anti-human HSC70 mouse monoclonal antibodies were obtained from Pharmingen, BD Biosciences (Le Pont de Claix, France) and Santa Cruz Biotechnology TPA exposure as described. 27 Human peripheral blood monocytes were obtained from healthy donors with informed consent and purified using a CD14 + monocyte isolation kit with a lightscattering column according to the manufacturer's instructions (Miltenyi Biotech, Paris, France) and then incubated (0.5 x 10 6 /mL) for up to 6 days in RPMI-1640 medium (Lonza, Verviers, Belgium), 10% fetal calf serum (Lonza), in the presence of 100 ng/mL M-CSF to trigger their differentiation into macrophages. The differentiated phenotype was identified by a flow cytometry analysis of the cell surface expression of CD11b (U937 and THP-1 cells) or CD71 (human macrophages) as described.
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Cell extracts, immunoprecipitation, cell fractionation and immunoblot analysis
Whole-cell lysates were prepared by incubating the cells in lysis buffer (Tris-HCl 50 mM pH 8, NaCl 150 mM, Triton X-100 1 %) in the presence of protease inhibitors and then sonicated.
Extracts for phosphoprotein analysis were prepared by lysing the cells in lysis buffer (TrisHCl 50 mM pH 7.4, NaCl 50 mM, Na 4 P 2 O 7 15 mM, NaF 5 mM, Na 3 VO 4 , Triton X-100 1 %) in the presence of protease inhibitors and then centrifugated to remove cellular debris. Cell fractionation and immunoprecipitation experiments were performed as described. 28 For personal use only. on June 9, 2017. by guest www.bloodjournal.org From Undifferentiated THP-1 and U937 cells and human blood monocytes were nucleoporated with siRNA using AMAXA nucleofector kit (AMAXA, Köln, Germany) following the manufacturer's instructions. The siRNA sequences were cIAP1 siRNA sequence 1 (forward:
5'-GGCCAAGAGUUUGUUGAUtt-3'; reverse: 5'-AUCAACAAACUCUUGGCCtt-3'; Eurogentec, Seraing, Belgium); cIAP1 sequence 2 (121288) designed and purchased from Ambion (Courtaboeuf, France), TRAF2 siRNA sequence 1 (Hs_TRAF2_4) and sequence 2 (Hs_TRAF2_5) both designed and provided by Qiagen (Courtaboeuf, France).
Retroviral supernatant production and transduction protocol
A mutated form of TRAF2 within the RING and the fourth zinc finger domain (TRAF2*) (kindly provided by Ze'ev Ronai), cIAP1 wt and cIAP1-ΔRING (deleted for the RING domain) cDNAs were inserted into a bicistronic retroviral pMX-IG vector (kindly provided by Toshio Kitamura) that harbors the internal ribosomal entry site and simultaneously expresses GFP with the protein of interest. HEK 293T cells (ATCC) were grown in DMEM-10% fetal calf serum to 70% confluence in a 6 well culture plates and transfected using For personal use only. on June 9, 2017. by guest www.bloodjournal.org From
Results
Monocyte differentiation into macrophages is associated with a decrease in TRAF2
expression.
We performed an immunoblot analysis of TRAF2 expression in human peripheral blood monocytes undergoing differentiation into macrophages upon exposure to M-CSF. We observed an increase in TRAF2 expression at day 1, then a time-dependent decrease in the protein level ( Figure 1A , two independent samples). A similar observation was made in THP-1 and U937 cell lines, two monoblastic cell lines whose differentiation into macrophages was induced by exposure to the phorbol ester 12-0-tetradecanoyl-phorbol 13-acetate (TPA). In these cell lines, TRAF2 expression increased during the first hours of the differentiation process, then progressively decreased ( Figure 1A ). In THP-1 cells ( Figure 1B 
cIAP1 is involved in the differentiation-associated TRAF2 degradation.
The RING domain containing protein cIAP1 was demonstrated to be an E3 enzyme in the ubiquitylation process that leads to TRAF2 degradation by the proteasome machinery. 12, 13, 23 Co-immunoprecipitation experiments demonstrated that cIAP1 interacted with TRAF2 in Addition of the proteasome inhibitor MG132 to the culture medium 7 hours before the coimmunoprecipitation experiment permitted the TRAF2 / cIAP1 interaction to be partially recovered (Figure 2A ). To determine whether cIAP1 was involved in the degradation of TRAF2 that accompanies the macrophagic differentiation, we first exposed the cells to the IAP inhibitor Smac-N7, a cell permeable peptide made of the 7 N-terminal amino-acids of the endogenous IAP inhibitor, Smac. This inhibitory peptide was shown to prevent cIAP1-TRAF2 interaction. 29 Its addition to the culture medium partially prevented the differentiation-associated degradation of TRAF2 ( Figure 2B ). We also used a retrovirus vector to introduce in THP-1 cells an E3-defective mutant of cIAP1 in which the RING domain has been deleted (cIAP1-ΔRING). The expression of this cIAP1 dominant negative mutant 12 delayed the degradation of TRAF2 in THP-1 cells undergoing differentiation into macrophages ( Figure 2C ). In contrast, retrovirus-mediated overexpression of wild-type cIAP1 decreased the basal level of TRAF2 expression in undifferentiated cells ( Figure 2C ). Lastly, the use of two cIAP1-targetting siRNAs that specifically decreased cIAP1 expression ( Figure   2D , left panel) prevented the differentiation-associated TRAF2 depletion ( Figure 2D , right panel). Interestingly, when introduced into macrophages obtained by ex vivo differentiation of peripheral blood monocytes by M-CSF, the two cIAP1 siRNAs induced a drastic increase in TRAF2 level ( Figure 2E ), suggesting that cIAP1 was also required for maintaining a low level of TRAF2 protein in differentiated macrophages.
Differentiation-associated TRAF2 degradation occurs in the golgi apparatus-associated compartment.
We previously showed that, in cells undergoing differentiation, cIAP1 migrated from the nucleus to the cytoplasm through a NES, CrmA-dependent mechanism, to concentrate at the Golgi apparatus surface, 26 which was confirmed in Figure 3A&E . The expression of cIAP1 in the cytoplasm is inversely correlated with TRAF2 expression ( Figure 3A) . Leptomycin B blocked the nuclear export of cIAP1 ( Figure 3B , upper panel) and prevented the decrease in TRAF2 protein expression ( Figure 3B ) associated with differentiation. In undifferentiated cells, TRAF2 is expressed both in the nuclear and in the cytoplasm-enriched fractions ( Figure   3C ). Along macrophage formation, TRAF2 protein expression first increases in the cytoplasm ( Figure 3C ), which is in accordance with results obtained in whole cell extracts ( Figure 1A ), then decreases when cIAP1 accumulates in this cellular compartment. Conversely, nuclear TRAF2 expression remains unchanged ( Figure 3C ). Fluorescence microscopy analyses confirmed that, in undifferentiated cells, TRAF2 was expressed in both the cytoplasm and the nucleus ( Figure 3D&E ). During the first hours of TPA-induced differentiation, TRAF2 accumulated at the cytoplasm periphery and formed clusters ( Figure 3D) . Then, TRAF2
labelling gets progressively less bright coinciding with TRAF2 depletion in the cytoplasm.
After 24 hours of TPA treatment, TRAF2 was mainly detected in the nuclear compartment ( Figure 3D&E ). Inhibition of the proteasome machinery by addition of MG132 for 7 hours or lactacystin for 4 hours before immunofluorescence staining revealed that the adaptor protein co-localized with cIAP1 and the Golgi apparatus marker GM130 in a cytoplasm perinuclear structure ( Figure 3E and supplementary Figure 1 for controls). These results suggest that TRAF2 is degraded in the Golgi apparatus-associated compartment by a cIAP1 and proteasome-dependent process.
TRAF2 is a positive regulator of macrophage differentiation
The initial increase in TRAF2 mRNA and protein expression ( Figure 1 ) and its clustering at the cell periphery ( Figure 3D ) suggested that TRAF2 might play a role in the first phases of the differentiation process. This TRAF2 expression increase was efficiently prevented by the use of 2 independent and specific siRNAs in human blood monocytes and THP-1 cells ( Figure 4A, upper panel) . TRAF2-targeting siRNAs prevented their differentiation induced by M-CSF (CD71 expression) and TPA (CD11b expression) exposure, respectively ( Figure 4A, lower panel) . We 28 and others 30 previously showed that macrophage differentiation required a moderate and transient activation of NF-κB transcription factor.
Here, we show that macrophage differentiation is associated with a nuclear translocation of p65 NF-κB subunit ( Figure 4B ) and a decrease in Iκ-Bα expression ( Figure 4C ). The two TRAF2-targeting siRNAs prevent both Iκ-Bα decrease ( Figure 4D ) and p65 nuclear redistribution ( Figure 4E ). Figure   2) . In order to reduce the differentiation associated degradation of exogenous TRAF2 , we used a mutated form of the protein (TRAF2*) that was shown to resist more efficiently than wild-type protein to proteasome-mediated degradation. 7 Retrovirus mediated expression of Figure 5B ) and this overexpression was sufficient to prevent macrophage differentiation, as evidenced by studying CD11b expression at the cell surface ( Figure 5C ).
TRAF2 overexpression also induced an ~20% decrease in the ability of cells to engulf bacteria, a differentiation-associated property ( Figure 5D ). An EMSA also suggested that overexpression of TRAF2* or the cIAP1-ΔRING construct partially prevented the downregulation of NF-kB activity that is required for the differentiation into macrophages to progress. (Figure 5E ).
TRAF2 modulates the response of mature macrophages to CD40L.
As low level of TRAF2 expression was maintained through a cIAP1-dependent mechanisms in macrophages (see Figure 2E ), we wondered whether this regulation was involved in macrophage specific functional properties. Macrophages obtained by a 6-day exposure of peripheral blood monocytes to M-CSF were transiently transfected with an empty vector or a wild-type TRAF2 encoding vector. In these conditions, TRAF2-protein level in transfected macrophages was almost similar to that observed in primary monocytes ( Figure   6A ). These cells were stimulated for 24 hours with 500 ng/mL CD40L and cell supernatants were analysed by the use of a cytokine antibody array ( Figure 6B ). Of the 36 cytokines analysed, 15 were detected in CD40L stimulated-macrophage supernatants. The level of eleven of them, including C5a, IL-1β, IL-1ra, IL-8, IL-16, IP-10, I-TAC, MCP-1, MIF, Serpin E1 and TNF-α, was lower in the supernatant of TRAF2-overexpressing macrophages than in the supernatant of macrophages transfected with the empty vector ( Figure 6B ). An ELISA quantification confirmed that TRAF2 restoration inhibited MCP-1 (~30%) and IL-8 (~35%) Figure 6C ) and this effect was maintained over time ( Figure 6D ). siRNA-mediated decrease in cIAP1 expression also decreased the secretion of interleukin-8 (IL-8) and MCP-1 ( Figure 6E ).
A quantitative real-time-PCR analysis showed that TRAF2 overexpression ( Figure 7A ) as well as siRNA-mediated decrease in cIAP1 expression ( Figure 7C ) decreased the expression of IL-8 and MCP-1 mRNA, which was confirmed with time ( Figure 7B ). JNK was shown to be one of the key pathways that control the cytokine secretion in response to CD40L in macrophages. 31 Inhibition of JNK by SP600123 abolished CD40L induced increase in MCP-1, and IL-8 mRNA ( Figure 7D ). In this setting, TRAF2 silencing did not interfere with CD40-induced JNK activation (not shown) but TRAF2 overexpression delayed and rapidly downregulated JNK activation ( Figure 7E ). Altogether, these data suggest that TRAF2, while being required for optimal differentiation at the beginning of the process, must be subsequently down-regulated for an optimal cytokine response of macrophages to CD40L and c-IAP1 is involved in this down-regulation.
Discussion
Once in the tissues, peripheral blood monocytes evolve into a variety of terminally differentiated cells, depending on signals received from the microenvironment. The molecular mechanisms that sustain the differentiation processes and confer to differentiated cells their specific properties are only partially depicted. Here, we show that the adaptor molecule TRAF2 is both a positive (initial phase) and a negative (secondary phase) regulator of the differentiation of monocytes into macrophages. The protein must be degraded by a proteasome-dependent mechanism that involves cIAP1 for terminal differentiation of with Iκ-Bα degradation and the nuclear translocation of NF-κB p65 subunit, two events that are prevented by TRAF2 silencing. These results suggest that TRAF2 takes parts in the canonical NF-κB activating pathway during initial phase of monocyte differentiation into macrophages.
Later on in the differentiation process, TRAF2 is degraded by the proteasome system , which was demonstrated to be an important regulatory event in various signalling pathways. 8, 11, 13, 17, 19 Overexpression of a TRAF2 mutant known to resist to proteasomemediated degradation prevent the progression of macrophage differentiation and interfere with the down-regulation of NF-κB activity. Altogether, our results suggest that initial
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From accumulation of TRAF2 and its subsequent degradation by a cIAP1-dependent process play a role in the time-dependent modulation of NF-κB activity along the differentiation process. 28, 30 TRAF2 is targeted for proteolytic degradation by ubiquitylation. The molecule is composed of an N-terminal RING domain 35 that characterizes E3 ubiquitin ligase activity 36 and was proposed to promote its own ubiquitylation. 19 Siah2 protein is also a RINGcontaining protein that can mediate TRAF2 ubiquitylation to target the protein for degradation under stressfull conditions. 17 cIAP1 is another RING-containing ubiquitin ligase that can trigger TRAF2 ubiquitylation and proteasome-dependent degradation, e.g. upon engagement of TNFR2. 8, 12, 13 We have previously shown that cIAP1 is required for optimal differentiation of monocytes into macrophages. 25 We show here that cIAP1 is one of the E3 ligases involved in the proteasome-dependent degradation of TRAF2 along this differentiation process. Since the effect of cIAP1 inhibition on differentiation-associated TRAF2 downregulation was only partial, we can not rule out a function for TRAF2 itself, Siah2 or other E3 in this event.
We also observed that the degradation of TRAF2 in monocytes undergoing macrophage differentiation was associated with the translocation of the protein to a perinuclear structure. By inhibiting the proteasome, we demonstrated that TRAF2 co-localizes with cIAP1 and proteins of the Golgi apparatus associated compartment. 26 TRAF2 was shown also to co-localizes with endoplasmic reticulum markers, including the cognate E2 enzyme Ubc6. Interestingly, Ubc6 behaves as the E2 enzyme for cIAP1 E3 activity leading to TRAF2 degradation. 8 Altogether, these observations indicate that cIAP1 interaction with TRAF2 that leads to its proteasome-mediated degradation along macrophage formation might occur in the Golgi-associated compartment.
TRAF2 depletion sensitizes specific cells to TNF-α induced apoptosis. 6, 11, 14, 18, 19 The premature death of TRAF2-deficient mice was related to an increased sensitivity of thymocytes and hematopoietic progenitors to TNF-induced cell death. 10 Accordingly, cIAP1- 41, 42 Association of cIAP1 with the CD40 cytoplasmic domain complex was dependent on the presence of an intact TRAF1/2/3 binding site but the role of cIAP1 in this complex remained undetermined. 41, 42 We demonstrate that cIAP1-mediated TRAF2 depletion associated with macrophage differentiation facilitates the cytokine secretion in response to CD40 stimulation. Accordingly, an elevated level of TNF-α has been observed in sera from TRAF2-deficient mice 10 that is responsible for the premature death of the animals. 43 The TRAF-dependent signalling pathway activated by CD40L depends on the cell type and the differentiation stage. 44 In macrophages, CD40 pro-inflammatory signals involve the adaptor TRAF6 and the ERK and JNK-dependent pathways. 31, 39, 45 Macrophages that harbour a CD40 mutant unable to bind TRAF2 still produced cytokine in response to CD40L
showing that TRAF2 is dispensable for its function. 31, 46 The present results show that TRAF2 actually negatively regulates this pathway by preventing JNK activation and downstream production of MCP-1 and IL-8 in response to CD40L. This negative effect of TRAF2 on
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From macrophage response to CD40L could possibly be mediated by heterodimerization with another TRAF such as TRAF6 as it has been observed in epithelial cells. 9, 16, 47 While TRAF2 is a positive regulator of the differentiation of monocytes into macrophages, its down-regulation by cIAP1 in mature macrophages may be part of a coordinated response that prepares these cells to their various functions, i.e. appropriate response to CD40-ligand. When associated to the Golgi apparatus, cIAP1 could regulate the expression of other signalling regulators that include NEMO/IKKγ, 48 RIP1, 49 ASK1, 50 and NIK 51 which were demonstrated to be cIAP1 ubiquitin targets. Further studies will determine whether these kinases are cIAP1 targets in this differentiation setting and how their modulations contribute to the macrophage functions.
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Legends Figure 1. TRAF2 expression decreases along differentiation into macrophages. (A)
Immunoblot analysis of TRAF2 expression in peripheral blood monocytes exposed to 100 ng/mL M-CSF and in THP-1 and U937 cells exposed to 20 nM TPA for indicated times. For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 
